Jeffrey Infante

Jeffrey Infante

UNVERIFIED PROFILE

Are you Jeffrey Infante?   Register this Author

Register author
Jeffrey Infante

Jeffrey Infante

Publications by authors named "Jeffrey Infante"

Are you Jeffrey Infante?   Register this Author

100Publications

13178Reads

48Profile Views

Safety profile of avelumab in patients with advanced solid tumors: A pooled analysis of data from the phase 1 JAVELIN solid tumor and phase 2 JAVELIN Merkel 200 clinical trials.

Cancer 2018 05 22;124(9):2010-2017. Epub 2018 Feb 22.

Genitourinary Malignancies Branch, Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.31293DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5947549PMC
May 2018

Long-Term Outcomes in Patients With BRAF V600-Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib.

J Clin Oncol 2018 03 9;36(7):667-673. Epub 2017 Oct 9.

Georgina V. Long, University of Sydney, and Royal North Shore Hospital; Richard Kefford, Macquarie University, Sydney, and Westmead Hospital, Westmead, New South Wales; Jonathan Cebon, Ludwig Institute for Cancer Research, Melbourne, Victoria, Australia; Zeynep Eroglu, Moffitt Cancer Center, Tampa, FL; Jeffrey Infante, Tennessee Oncology; Douglas B. Johnson, Vanderbilt-Ingram Cancer Center, Nashville, TN; Sapna Patel, The University of Texas MD Anderson Cancer Center, Houston, TX; Adil Daud, University of California, San Francisco, San Francisco; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles, CA; Rene Gonzalez, University of Colorado, Denver, CO; Lynn Schuchter, University of Pennsylvania, Philadelphia, PA; William Sharfman, Sidney Kimmel Cancer Center, Baltimore, MD; Robert McWilliams, Mayo Clinic, Rochester, MN; Mario Sznol, Yale University, New Haven, CT; Suman Redhu, Eduard Gasal, and Bijoyesh Mookerjee, Novartis, East Hanover, NJ; Jeffrey Weber, New York University Langone Medical Center, New York, NY; and Keith T. Flaherty, Dana-Farber/Harvard Cancer Center, Boston, MA.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2017.74.1025
Publisher Site
http://dx.doi.org/10.1200/JCO.2017.74.1025DOI Listing
March 2018

Phase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-Inducible Factor-2α Antagonist in Patients With Previously Treated Advanced Clear Cell Renal Cell Carcinoma.

J Clin Oncol 2018 03 19;36(9):867-874. Epub 2017 Dec 19.

Kevin D. Courtney and James Brugarolas, University of Texas Southwestern Medical Center; Naseem J. Zojwalla, Ann M. Lowe, Keshi Wang, Eli M. Wallace, and John A. Josey, Peloton Therapeutics, Dallas, TX; Jeffrey R. Infante, TN Oncology and Sarah Cannon Research Institute, Nashville, TN; Elaine T. Lam, University of Colorado Cancer Center, Aurora, CO; Robert A. Figlin, Cedars-Sinai Medical Center, Los Angeles, CA; Brian I. Rini, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; Toni K. Choueiri, Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.74.2627DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5946714PMC
March 2018

Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study.

J Clin Oncol 2017 Dec 5;35(34):3851-3858. Epub 2017 Jul 5.

Hans J. Hammers, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; Elizabeth R. Plimack, Fox Chase Cancer Center, Philadelphia, PA; Jeffrey R. Infante, Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Brian I. Rini, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; David F. McDermott, Beth Israel Deaconess Medical Center, Dana-Farber/Harvard Cancer Center, Boston, MA; Lionel D. Lewis, The Geisel School of Medicine and The Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center, Lebanon, NH; Martin H. Voss, Memorial Sloan Kettering Cancer Center, New York, NY; Padmanee Sharma, MD Anderson Cancer Center, University of Texas, Houston, TX; Sumanta K. Pal, City of Hope Comprehensive Cancer Center, Duarte, CA; Albiruni R. Abdul Razak, Princess Margaret Cancer Centre, Toronto, Ontario; Christian Kollmannsberger, British Columbia Cancer Agency, Vancouver, British Columbia; Daniel Y.C. Heng, Tom Baker Cancer Center, University of Calgary, Calgary; Jennifer Spratlin, Cross Cancer Institute, University of Alberta, Edmonton, Alberta, Canada; M. Brent McHenry, Bristol-Myers Squibb, Princeton, NJ; and Asim Amin, Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2016.72.1985
Publisher Site
http://dx.doi.org/10.1200/JCO.2016.72.1985DOI Listing
December 2017

Avelumab, an Anti-Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study.

J Clin Oncol 2017 Jul 4;35(19):2117-2124. Epub 2017 Apr 4.

Andrea B. Apolo and James L. Gulley, National Institutes of Health, Bethesda, MD; Jeffrey R. Infante, Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Ani Balmanoukian, The Angeles Clinic & Research Institute; Alain C. Mita, Cedars Sinai Medical Center, Los Angeles; Karen Kelly, University of California-Davis, Sacramento; Marko Srdanov, Dako North America, Carpinteria, CA; Manish R. Patel, Florida Cancer Specialists & Research Institute, Sarasota, FL; Ding Wang, Henry Ford Hospital, Detroit, MI; Anthony E. Mega, The Warren Alpert Medical School at Brown University; Howard Safran, The Miriam Hospital, Providence; Howard Safran, Newport Hospital, Newport, RI; Carolyn D. Britten, Medical University of South Carolina, Charleston, SC; Alain Ravaud, CHU de Bordeaux, Bordeaux, France; Thomas E. Stinchcombe, Duke University Medical Center, Durham, NC; Arnold B. Gelb and Kevin Chin, EMD Serono, Billerica, MA; and Michael Schlichting, Merck, Darmstadt, Germany.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2016.71.6795
Publisher Site
http://dx.doi.org/10.1200/JCO.2016.71.6795DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5493051PMC
July 2017

Safety and Activity of Varlilumab, a Novel and First-in-Class Agonist Anti-CD27 Antibody, in Patients With Advanced Solid Tumors.

J Clin Oncol 2017 Jun 2;35(18):2028-2036. Epub 2017 May 2.

Howard A. Burris and Jeffrey R. Infante, Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN; Stephen M. Ansell, Mayo Clinic, Rochester, MN; John J. Nemunaitis, Mary Crowley Cancer Research Center, Dallas, TX; Geoffrey R. Weiss and Timothy Bullock, University of Virginia, Charlottesville, VA; Victor M. Villalobos and Branimir I. Sikic, Stanford Cancer Institute, Stanford, CA; Matthew H. Taylor, Oregon Health & Science University, Portland, OR; Donald W. Northfelt, Mayo Clinic, Scottsdale, AZ; William E. Carson III, The Ohio State University, Columbus, OH; Thomas R. Hawthorne, Thomas A. Davis, Michael J. Yellin, and Tibor Keler, Celldex Therapeutics, Hampton, NJ.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2016.70.1508
Publisher Site
http://dx.doi.org/10.1200/JCO.2016.70.1508DOI Listing
June 2017

An Aqueous-Based Approach for Fabrication of PVDF/MWCNT Porous Composites.

Sci Rep 2017 05 11;7(1):1716. Epub 2017 May 11.

Department of Mechanical and Aerospace Engineering, Rutgers, The state University of New Jersey, 98 Brett Road, Piscataway, New Jersey, 08854-8058, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41598-017-01770-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5431977PMC
May 2017

Safety, Antitumor Activity, and Immune Activation of Pegylated Recombinant Human Interleukin-10 (AM0010) in Patients With Advanced Solid Tumors.

J Clin Oncol 2016 10;34(29):3562-3569

Aung Naing, Rivka R. Colen, David S. Hong, and Nizar M. Tannir, MD Anderson Cancer Center, Houston; Kyriakos P. Papadopoulos and Drew R. Rasco, START Center for Cancer Care, San Antonio, TX; Karen A. Autio, Memorial Sloan Kettering Cancer Center, New York, NY; Patrick A. Ott, Dana-Farber Cancer Institute, Boston, MA; Manish R. Patel, Sarah Cannon Research Institute/Florida Cancer Specialists, Sarasota, FL; Deborah J. Wong, University of California Los Angeles, Los Angeles; Melinda Whiteside, John B. Mumm, Ivan H. Chan, Peter Van Vlasselaer, and Martin Oft, ARMO BioSciences, Redwood City, CA; Gerald S. Falchook, Sarah Cannon Research Institute at HealthONE, Denver, CO; Shubham Pant, Oklahoma University, Oklahoma City, OK; and Johanna C. Bendell, Todd M. Bauer, and Jeffrey R. Infante, Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.68.1106DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5657013PMC
October 2016

Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors.

Int J Nanomedicine 2015 10;10:1201-9. Epub 2015 Feb 10.

UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, USA ; UNC Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA ; UNC Institute for Pharmacogenomics and Individualized Therapy, University of North Carolina, Chapel Hill, NC, USA ; Carolina Center for Cancer Nanotechology Excellence, University of North Carolina, Chapel Hill, NC, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/IJN.S62911DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4334335PMC
May 2016

Phase I Study of LY2606368, a Checkpoint Kinase 1 Inhibitor, in Patients With Advanced Cancer.

J Clin Oncol 2016 05 4;34(15):1764-71. Epub 2016 Apr 4.

David Hong, Filip Janku, Ly M. Nguyen, Aung Naing, Sarina Piha-Paul, Faye M. Johnson, and Razelle Kurzrock, The University of Texas MD Anderson Cancer Center, Houston, TX; Jeffrey Infante, Suzanne Jones, Howard Burris, Todd M. Bauer, and Johanna Bendell, Sarah Cannon Research Institute; Jeffrey Infante, Howard Burris, Todd M. Bauer, and Johanna Bendell, Tennessee Oncology, Nashville, TN; and Lisa Golden, Scott Hynes, Ji Lin, and Aimee Bence Lin, Eli Lilly, Indianapolis, IN.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.64.5788DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5321045PMC
May 2016

A phase I dose escalation study of NK012, an SN-38 incorporating macromolecular polymeric micelle.

Cancer Chemother Pharmacol 2016 05 9;77(5):1079-86. Epub 2016 Apr 9.

Sarah Cannon Research Institute, 3322 West End Avenue, Suite 900, Nashville, TN, 37203, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-016-2986-xDOI Listing
May 2016

Targeting CDK4/6 in patients with cancer.

Cancer Treat Rev 2016 Apr 8;45:129-38. Epub 2016 Mar 8.

Sarah Cannon Research Institute/Tennessee Oncology PLLC, 250 25th Avenue North, Nashville, TN 37203, United States. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2016.03.002DOI Listing
April 2016

Atezolizumab, an Anti-Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study.

J Clin Oncol 2016 Mar 11;34(8):833-42. Epub 2016 Jan 11.

David F. McDermott, Beth Israel Deaconess Medical Center, Boston, MA; Jeffrey A. Sosman, Vanderbilt University School of Medicine; Jeffrey R. Infante, Sarah Cannon Research Institute, Nashville, TN; Mario Sznol, Yale Cancer Center, New Haven, CT; Christophe Massard, Gustave Roussy, Villejuif Cedex, France; Michael S. Gordon, Pinnacle Oncology Hematology, Scottsdale, AZ; Omid Hamid, Angeles Clinic and Research Institute, Santa Monica; Marcella Fassò, Yan V. Wang, Wei Zou, Priti S. Hedge, and Gregg D. Fine, Genentech, South San Francisco, CA; John D. Powderly, Carolina BioOncology Institute, Huntersville, NC; and Thomas Powles, Barts Cancer Institute Centre for Experimental Cancer Medicine and the Royal Free National Health Service Trust, Queen Mary University of London, London, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.63.7421DOI Listing
March 2016

Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib.

J Clin Oncol 2016 Mar 25;34(8):871-8. Epub 2016 Jan 25.

Georgina V. Long, Melanoma Institute Australia; The University of Sydney; Richard F. Kefford, Melanoma Institute Australia; The University of Sydney; Macquarie University, Sydney; Westmead Hospital, Westmead; Jonathan Cebon, Austin Health, Melbourne, Victoria, Australia; Jeffrey S. Weber and Ragini Kudchadkar, Moffitt Cancer Center, Tampa, FL; Jeffrey R. Infante and Howard A. Burris III, Sarah Cannon Research Institute/Tennessee Oncology; Kevin B. Kim, California Pacific Medical Center; Adil Daud, Alain Algazi, University of California, San Francisco, San Francisco; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles, CA; Rene Gonzalez, Karl Lewis, University of Colorado; Gerald S. Falchook, Sarah Cannon Research Institute at HealthONE, Denver, CO; Jeffrey A. Sosman, Igor Puzanov, Vanderbilt University Medical Center, Nashville, TN; Lynn Schuchter, University of Pennsylvania Abramson Cancer Center; Nageatte Ibrahim, Elizabeth Cunningham, Merck; Peng Sun, Amy S. Kline, Heather Del Buono, Diane Opatt McDowell, GlaxoSmithKline, Philadelphia, PA; Donald Lawrence and Kiran Patel, Incyte Corporation, Wilmington, DE; and Keith T. Flaherty, Massachusetts General Hospital Cancer Center, Boston, MA.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2015.62.9345
Publisher Site
http://dx.doi.org/10.1200/JCO.2015.62.9345DOI Listing
March 2016

Erratum to: Phase 1 study of oral TAS-102 in patients with refractory metastatic colorectal cancer.

Cancer Chemother Pharmacol 2016 Feb;77(2):439

Sarah Cannon Research Institute/Florida Cancer Specialists, 600 N. Cattlemen Road, Suite 200, Sarasota, FL, 34232, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-015-2890-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4969883PMC
February 2016

Molecular Pathways: Fatty Acid Synthase.

Clin Cancer Res 2015 Dec 30;21(24):5434-8. Epub 2015 Oct 30.

Sarah Cannon Research Institute, Nashville, Tennessee.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/content/early/2015/10/
Web Search
http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-15-0126DOI Listing
December 2015

Phase 1 study of oral TAS-102 in patients with refractory metastatic colorectal cancer.

Cancer Chemother Pharmacol 2015 Nov 14;76(5):925-32. Epub 2015 Sep 14.

Sarah Cannon Research Institute/Florida Cancer Specialists, 600 N. Cattlemen Road, Suite 200, Sarasota, FL, 34232, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-015-2850-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4612319PMC
November 2015

Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors.

J Clin Oncol 2015 Oct 31;33(30):3401-8. Epub 2015 Aug 31.

Josep Tabernero, Rodrigo Dienstmann, Barbara Adamo, and Jordi Rodon, Vall d'Hebron University Hospital and Institute of Oncology, Universitat Autònoma de Barcelona, Barcelona; Emiliano Calvo, START Madrid, Centro Integral Oncológico Clara Campal; Victor Moreno, START Madrid, Hospital Fundación Jiménez Díaz, Madrid, Spain; Rastislav Bahleda, Anas Gazzah, and Jean-Charles Soria, Gustave Roussy Cancer Campus and University Paris-Sud, Villejuif; Antoine Italiano, Institut Bergonié, Bordeaux, France; Jeffrey R. Infante, Sarah Cannon Research Institute, Nashville, TN; Alain Mita, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA; Bob Zhong, Suso J. Platero, Moitreyee Chatterjee-Kishore, Vijay Peddareddigari, and Feng R. Luo, Janssen Research and Development, Raritan, NJ; and Johan W. Smit and Kim Stuyckens, Janssen Research and Development, Beerse, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.60.7341DOI Listing
October 2015

Phase 1b study of the oral gemcitabine 'Pro-drug' LY2334737 in combination with capecitabine in patients with advanced solid tumors.

Invest New Drugs 2015 Apr 3;33(2):432-9. Epub 2015 Feb 3.

Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-015-0207-9DOI Listing
April 2015

Targeting PI3 kinase in cancer.

Pharmacol Ther 2015 Feb 18;146:53-60. Epub 2014 Sep 18.

Sarah Cannon Research Institute, Nashville, TN, USA; Tennessee Oncology, PLLC, Nashville, TN, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pharmthera.2014.09.006DOI Listing
February 2015

Prognostic factors of survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer.

Oncologist 2015 Feb 12;20(2):143-50. Epub 2015 Jan 12.

Medical Oncology Department, Vall d'Hebron University Hospital and Institute of Oncology, Universitat Autònoma de Barcelona, Barcelona, Spain; Division of Oncology, University of Washington, Seattle, Washington, USA; Department of Oncology/Hematology, Sarah Cannon Research Institute, Nashville, Tennessee, USA; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA; Department of Oncology, Peninsula Oncology Centre, Monash University, Frankston, Victoria, Australia; Division of Medical Oncology, University of Colorado Cancer Center, Aurora, Colorado, USA; Division of Clinical Oncology, Medizinische Universität Wien, Vienna, Austria; Mayo Clinic, Scottsdale, Arizona, USA; Department of Oncology, Prince of Wales Hospital, Randwick, New South Wales, Sydney, Australia; Celgene Corporation, Summit, New Jersey, USA; Department of Oncology, Virginia G. Piper Cancer Center at Scottsdale Healthcare/TGen, Scottsdale, Arizona, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2014-0394DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4319641PMC
February 2015

Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma.

Invest New Drugs 2014 Dec 22;32(6):1246-57. Epub 2014 Aug 22.

MD, FACP; MD Anderson Cancer Center, Department of Genitourinary Medical Oncology, 1155 Pressler St, Unit 1374, Houston, TX, 77030, USA,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-014-0151-0DOI Listing
December 2014

Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor.

J Clin Oncol 2014 Nov 6;32(33):3697-704. Epub 2014 Oct 6.

Douglas B. Johnson and Jeffrey A. Sosman, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center; Jeffrey R. Infante and Howard A. Burris III, Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN; Keith T. Flaherty and Donald P. Lawrence, Massachusetts General Hospital Cancer Center, Boston MA; Jeffrey S. Weber and Geoffrey T. Gibney, Moffitt Cancer Center, Tampa, FL; Kevin B. Kim and Gerald S. Falchook, University of Texas MD Anderson Cancer Center, Houston, TX; Richard F. Kefford and Georgina V. Long, Melanoma Institute Australia, University of Sydney and Westmead Hospital, Sydney, New South Wales; Jonathan Cebon, Joint Ludwig-Austin Oncology Unit, Austin Health, Melbourne, Victoria, Australia; Omid Hamid, Angeles Clinic and Research Institute, Los Angeles; Alain Algazi and Adil Daud, University of California, San Francisco, San Francisco, CA; Lynn Schuchter, University of Pennsylvania Abramson Cancer Center; Nageatte Ibrahim, Peng Sun, Shonda Little, and Elizabeth Cunningham, GlaxoSmithKline, Philadelphia, PA; William H. Sharfman, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD; Robert R. McWilliams, Mayo Clinic, Rochester, MN; Mario Sznol, Yale University School of Medicine and Smilow Cancer Center, Yale-New Haven Hospital, New Haven, CT; Karl Lewis and Rene Gonzalez, University of Colorado, Denver, CO; and Kiran Patel, Incyte, Wilmington, DE.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.57.3535DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4226803PMC
November 2014

Clinical impact of checkpoint inhibitors as novel cancer therapies.

Drugs 2014 Nov;74(17):1993-2013

Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville, TN, 37203, USA,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40265-014-0305-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4224737PMC
November 2014

Successful treatment with dabrafenib (GSK2118436) in a patient with ganglioglioma.

J Clin Oncol 2014 Oct 10;32(29):e98-e100. Epub 2014 Feb 10.

Sarah Cannon Research Institute; and Tennessee Oncology, Nashville, TN.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2013.48.6852
Publisher Site
http://dx.doi.org/10.1200/JCO.2013.48.6852DOI Listing
October 2014

Phase I dose-escalation study of LCL161, an oral inhibitor of apoptosis proteins inhibitor, in patients with advanced solid tumors.

J Clin Oncol 2014 Oct 11;32(28):3103-10. Epub 2014 Aug 11.

Jeffrey R. Infante, Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; E. Claire Dees, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC; Antony J. Olszanski, Fox Chase Cancer Center; Roger B. Cohen, Perelman School of Medicine, Philadelphia, PA; Shyeilla V. Dhuria and Suman Sen, Novartis Pharmaceuticals Corp, East Hanover, NJ; and Scott Cameron, Novartis Institutes for Biomedical Research, Cambridge, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.52.3993DOI Listing
October 2014

Dose selection, pharmacokinetics, and pharmacodynamics of BRAF inhibitor dabrafenib (GSK2118436).

Clin Cancer Res 2014 Sep 23;20(17):4449-58. Epub 2014 Jun 23.

Melanoma Institute Australia and University of Sydney, New South Wales, Australia. Westmead Institute for Cancer Research, Westmead Millennium Institute, and Department of Medical Oncology, Westmead Hospital, Sydney, New South Wales, Australia.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-14-0887DOI Listing
September 2014

Combined inhibition of BRAF and MEK in melanoma patients.

Lancet Oncol 2014 Aug 15;15(9):908-10. Epub 2014 Jul 15.

Cancer Research UK London Research Institute, and University College London Hospitals and Cancer Institute, London, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(14)70331-6DOI Listing
August 2014

A Phase I cardiac safety and pharmacokinetic study of tivozanib hydrochloride in patients with advanced solid tumors.

Clin Pharmacol Drug Dev 2014 07 9;3(4):284-9. Epub 2014 May 9.

Virginia G. Piper Cancer Center and TGen, Scottsdale, AZ, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cpdd.113DOI Listing
July 2014

Safety, pharmacokinetics, and pharmacodynamics of the DR5 antibody LBY135 alone and in combination with capecitabine in patients with advanced solid tumors.

Invest New Drugs 2014 Feb 16;32(1):135-44. Epub 2013 Apr 16.

Huntsman Cancer Institute, Division of Medical Oncology, University of Utah, 2000 Circle of Hope Drive, Suite 3380, Salt Lake City, UT, 84112, USA,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-013-9952-9DOI Listing
February 2014

Everolimus in combination with paclitaxel and carboplatin in patients with metastatic melanoma: a phase II trial of the Sarah Cannon Research Institute Oncology Research Consortium.

Melanoma Res 2013 Dec;23(6):468-73

aNebraska Cancer Specialists, Omaha, Nebraska bSarah Cannon Research Institute cTennessee Oncology, PLLC, Nashville, Tennessee dFlorida Cancer Specialists, Fort Myers, Florida, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CMR.0000000000000014DOI Listing
December 2013

Population pharmacokinetics of PEGylated liposomal CPT-11 (IHL-305) in patients with advanced solid tumors.

Eur J Clin Pharmacol 2013 Dec 30;69(12):2073-81. Epub 2013 Aug 30.

UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, 27599, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00228-013-1580-yDOI Listing
December 2013

Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.

N Engl J Med 2013 Oct 16;369(18):1691-703. Epub 2013 Oct 16.

From the Translational Genomics Research Institute, Phoenix, and Virginia G. Piper Cancer Center, Scottsdale - both in Arizona (D.D.V.H., R.K.R.); Cancer Specialists, Fort Myers, FL (T.E.); Arena Oncology Associates, Lake Success (F.P.A.), and Roswell Park Cancer Institute, Buffalo (W.W.M.) - both in New York; University of Washington, Seattle (E.G.C.); Sarah Cannon Research Institute-Tennessee Oncology, Nashville (J. Infante); Princess Margaret Hospital, Toronto (M.M.); Atlanta Cancer Care (T.S.) and Georgia Cancer Specialists (M.N.S.) - both in Atlanta; Blokhin Cancer Research Center, Moscow (S.A.T.); Southern Health, East Bentleigh, VIC (M.H.), Prince of Wales Hospital, Sydney (D.G.), and Bionomics, Thebarton, SA (J. Iglesias) - all in Australia; San Raffaele Scientific Institute, Milan (M.R.); Tom Baker Cancer Centre, Calgary, AB, Canada (S.D.); Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore (D.L.); University of Pittsburgh Medical Center, Pittsburgh (N.B.); Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona (J.T.); Centro Integral Oncológico Clara Campal, Madrid (M.H.); University Hospitals Leuven and Katholieke Universiteit Leuven, Leuven, Belgium (E.V.C.); and Celgene, Summit, NJ (X.W., M.F.R.).

View Article

Download full-text PDF

Source
http://www.nejm.org/doi/10.1056/NEJMoa1304369
Publisher Site
http://dx.doi.org/10.1056/NEJMoa1304369DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4631139PMC
October 2013

Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with erlotinib.

Invest New Drugs 2013 Aug 8;31(4):891-9. Epub 2012 Nov 8.

Roswell Park Cancer Institute, Elm & Carlton Streets, Buffalo, NY 14263, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-012-9887-6DOI Listing
August 2013

PARP inhibitors: pitfalls and promises.

Lancet Oncol 2013 Aug 28;14(9):798-9. Epub 2013 Jun 28.

Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN 37203, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(13)70276-6DOI Listing
August 2013

Pharmacokinetics of Irinotecan With and Without Panitumumab Coadministration in Patients With Metastatic Colorectal Cancer.

Clin Pharmacol Drug Dev 2013 Jul 15;2(3):205-12. Epub 2013 May 15.

Vancouver Cancer Center, BC Cancer Agency, Vancouver, BC, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cpdd.35DOI Listing
July 2013

Combination molecularly targeted drug therapy in metastatic melanoma: progress to date.

Drugs 2013 Jun;73(8):767-77

Sarah Cannon Research UK, 93 Harley St, London W1G 6AD, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40265-013-0049-8DOI Listing
June 2013